ArticleFrontiers in pharmacology2023
An international comparative analysis and roadmap to sustainable biosimilar markets.
Abstract read
In one paragraph
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake.Pharmaceutical medicine · 2026Review
- Navigating the Transition: A Scoping Review of System-Level Factors in Biosimilar Integration for Immune-Mediated Inflammatory Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Article
- Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability.Frontiers in pharmacology · 2025Article
- Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries.Therapeutic innovation & regulatory science · 2025Article
- Incidence of new fractures in older patients with osteoporosis receiving biosimilar teriparatide or reference products: A retrospective cohort study.British journal of clinical pharmacology · 2025Article
- Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America.Advances in therapy · 2024Review
- Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.Clinical and experimental medicine · 2024Review
- Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy.Therapeutic innovation & regulatory science · 2024Article
- From Sand to Excellence: A Deep Dive into Abu Dhabi's Rheumatology Landscape.Mediterranean journal of rheumatology · 2024Review
- Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients.Therapeutic advances in musculoskeletal disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Khalid A AlnaqbiTawam Hospital, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates.
Agnès BellangerPitié Salpétrière Hospital, Sorbonne University, Paris, France.
Alex BrillMatrix Global Advisors, American Enterprise Institute, Washington, DC, United States.
Gilberto Castañeda-HernándezCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.
Ana Clopés EstelaCatalan Institute of Oncology, Barcelona, Spain.
Olga Delgado SánchezEspases University Hospital, Palma de Mallorca, Spain.
Pilar García-AlfonsoMedical Oncology Department, Gregorio Marañón General University Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain.
Pius GygerIndependent Consultant, Zurich, Switzerland.
Daniel HeinrichInnlandet Hospital Trust, Gjøvik, Norway.
Germain HezardNile, Paris, France.
Adriana KakehasiFederal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
Cheryl KoehnArthritis Consumer Experts, Vancouver, BC, Canada.
Olivier MariotteNile, Paris, France.
Francesco MenniniEconomic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy.
Sonia Mayra Pérez-TapiaUnidad de Investigacion, Desarollo e Innovacion Médica y Biotecnológica (UDIMEB), Unidad de Desarollo e Investigacion de Bioterapeuticos (UDIBI), Instituto Politécnico Nacional, Ciudad de México, Mexico.
Michele PistollatoCharles River Associates, London, United Kingdom.
Rowan SaadaCharles River Associates, London, United Kingdom.
Tadanori SasakiShowa University, Shinagawa, Japan.
George TambassisAustralian Biosimilars Academy, Sydney, NSW, Australia.
Marc ThillDepartment of Gynecology and Gynecological Oncology, Agaplesion Markus Hospital, Frankfurt, Germany.
Gustavo WerutskyHospital São Lucas PUCRS, Porto Alegre, Brazil.
Tim WilsdonCharles River Associates, London, United Kingdom.
Steven SimoensKU Leuven, Leuven, Belgium.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
biosimilarcomparative analysismarket accesspolicysustainability
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.